Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Not All Hips Follow the Same Rules in THA
Dynamic modeling suggested flatback deformity lowered target combined anteversion, while stiff pelvic mobility narrowed the acceptable range
May 6, 2026
-
5 min